Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction

• Status: Unknown status
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is aimed to assess the efficacy of Human derived Transfer factor ( T-lymphocytes homogenate that contains small molecular weight (10 kDa) molecules: various IFNs, ILs, chemokines, endorfins, heat shock proteins) in decreasing rate and/or severity of infections in acute or chronic decompensations of liver cirrhosis and acute on chronic liver failure..

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Martin Janičko
• Collaborator: F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

Criteria

Inclusion Criteria:

• admission to hospital at participating liver units or ICUs or internal medicine wards with acute decompensation (AD) of advanced chronic liver disease or acute-on-chronic liver failure according to CLIF - C criteria

• ability to provide informed consent,

Exclusion Criteria:

• disapproval

• lymphoproliferative disorders

• liver transplantation in the past

• pregnancy

• suspected. chronic infection in risk locations

• CNS

• peritoneum

• Known virus-related immune deficiency

• malignancy

• severe heart failure (NYHA >= III)

• severe lung disease (COPD, GOLD>3)